Clinical Trial Detail

NCT ID NCT01425008
Title Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

Advanced Solid Tumor

melanoma

Therapies

MLN2480

Age Groups: senior adult

No variant requirements are available.